163 related articles for article (PubMed ID: 7774213)
1. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial.
Willatts SM; Radford S; Leitermann M
Crit Care Med; 1995 Jun; 23(6):1033-9. PubMed ID: 7774213
[TBL] [Abstract][Full Text] [Related]
2. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis.
Solomon LR; Cheesbrough JS; Ebah L; Al-Sayed T; Heap M; Millband N; Waterhouse D; Mitra S; Curry A; Saxena R; Bhat R; Schulz M; Diggle P
Am J Kidney Dis; 2010 Jun; 55(6):1060-8. PubMed ID: 20207458
[TBL] [Abstract][Full Text] [Related]
3. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.
Angstwurm MW; Engelmann L; Zimmermann T; Lehmann C; Spes CH; Abel P; Strauss R; Meier-Hellmann A; Insel R; Radke J; Schüttler J; Gärtner R
Crit Care Med; 2007 Jan; 35(1):118-26. PubMed ID: 17095947
[TBL] [Abstract][Full Text] [Related]
4. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
Dhainaut JF; Tenaillon A; Le Tulzo Y; Schlemmer B; Solet JP; Wolff M; Holzapfel L; Zeni F; Dreyfuss D; Mira JP
Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274
[TBL] [Abstract][Full Text] [Related]
5. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
[TBL] [Abstract][Full Text] [Related]
6. Incidence of gram-negative bacteraemia in sepsis syndrome. Implications for immunotherapy.
Willatts SM; Speller DC; Winter RJ
Anaesthesia; 1994 Sep; 49(9):751-4. PubMed ID: 7978126
[TBL] [Abstract][Full Text] [Related]
7. Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial.
Klek S; Szczepanek K; Hermanowicz A; Galas A
JPEN J Parenter Enteral Nutr; 2015 Mar; 39(3):331-5. PubMed ID: 24604029
[TBL] [Abstract][Full Text] [Related]
8. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
9. Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis.
Solomon LR; Cheesbrough JS; Bhargava R; Mitsides N; Heap M; Green G; Diggle P
Semin Dial; 2012; 25(2):233-8. PubMed ID: 21916999
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
11. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
[TBL] [Abstract][Full Text] [Related]
13. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis.
Vincent JL; Spapen H; Bakker J; Webster NR; Curtis L
Crit Care Med; 2000 Mar; 28(3):638-42. PubMed ID: 10752807
[TBL] [Abstract][Full Text] [Related]
14. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
Staubach KH; Schröder J; Stüber F; Gehrke K; Traumann E; Zabel P
Arch Surg; 1998 Jan; 133(1):94-100. PubMed ID: 9438767
[TBL] [Abstract][Full Text] [Related]
15. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
Trials; 2018 May; 19(1):264. PubMed ID: 29720244
[TBL] [Abstract][Full Text] [Related]
16. [The organ protective effects and timing of continuous blood purification in the treatment of severe sepsis:a double-blind randomized controlled trial].
Zhou R; Weng F; Dai W; Yan J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 Mar; 28(3):241-5. PubMed ID: 29917338
[TBL] [Abstract][Full Text] [Related]
17. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
[TBL] [Abstract][Full Text] [Related]
18. Effect of taurolidine on the normal eyelid and conjunctival flora.
Oguz H; Oguz E; Karadede S
Curr Eye Res; 2000 Nov; 21(5):851-5. PubMed ID: 11262606
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal taurolidine lavage in children with localised peritonitis due to appendicitis.
Schneider A; Sack U; Rothe K; Bennek J
Pediatr Surg Int; 2005 Jun; 21(6):445-8. PubMed ID: 15902475
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Abraham E; Naum C; Bandi V; Gervich D; Lowry SF; Wunderink R; Schein RM; Macias W; Skerjanec S; Dmitrienko A; Farid N; Forgue ST; Jiang F
Crit Care Med; 2003 Mar; 31(3):718-28. PubMed ID: 12626975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]